ML 3000

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

Wallace JL, Carter L, McKnight W, Tries S, Laufer S. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur J Pharmacol 271: 525–531, 27 Dec 1994
Article PubMed CAS Google Scholar
Algate DR, Augustin J, Atterson PR, et al. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals. Arzneimittel-Forschung 45: 159–165, Feb 1995
PubMed CAS Google Scholar
Euro Alliance. First clinical results of ML 3000, the parent drug of a new category of antiinflammatory agents, the Double Acting Antiinflammatory Drugs (DAAID). Company Communication: [2 pages], 11 Feb 1998
Google Scholar
Forest Laboratories Inc. Forest Laboratories announces positive results with ML3000 in early clinical trials. Media Release: [2 pages], 6 Oct 2000. Available from URL: http://www.frx.com
Google Scholar
Laufer S, Tries S, Augustin J, Dannhardt G. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittel-Forschung 44: 629–636, Part 1, May 1994
PubMed CAS Google Scholar
Laufer S, Tries S, Augustin J, et al. Acute and chronic antiinflammatory properties of [2,2-dimethyl-6-(4-chlorophenyl) -7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl-]-acetic acid. Arzneimittel-Forschung 45: 27–32, Jan 1995
PubMed CAS Google Scholar

ML 3000. Drugs R&D 3, 204–207 (2002). https://doi.org/10.2165/00126839-200203030-00014

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.